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Background
Jet nebulizer systems that are used to generate therapeutic
aerosols vary in their bronchodilating effect. The purpose
of the present study was to compare the bronchodilator
response in children with asthma between NE–C900
(OMRON), a new jet nebulizer and a commercially avail-
able nebulizer Redimist (RE).
Methods
Asthmatic children who have consented to the study and
aged 7 to 13 years with less than 70% of predicted PEFR
were randomized in to 2 groups (30 subjects in each
group). One group received Salbutamol solution (0.15mg
of Salbutamol nebulizer solution / kg body weight diluted
in 2ml of saline solution) nebulized by NE–C900 (OM).
The other group received. Salbutamol solution nebulized
by Redimist. At least 3 maneuvers were done to .obtain
the most acceptable PEFR before Salbutamol inhalation
and at 15 and 30 minutes after inhalation. Statistical analy-
sis was done using the ANOVA method to analyze the
changes in lung function at 15 and 30 min, Probability (p)
values of less than 0.05 was considered to indicate a statis-
tically significant difference.
Results
There was no difference in PEFR at baseline between
both groups. The difference in PEFR between that at
baseline and that at 15 minutes, as well as between that
at baseline and that at 30 minutes were highly significant
for both OM and RE groups. The improvement in PEFR
value for OM group was greater as compared to that of
the RE group at 15 min and the difference was statisti-
cally significant at p = 0.005. But the difference in the
improvement in PEFR between that at 15 minutes and
that at 30 minutes for both groupswas not statistically
significant. Comparing the variances of repeatedly mea-
sured PEFR values, ANOVA showed that there was con-
sistency in the data and no significant differences in
variances were detected in both groups at baseline,
15 minute or at 30 minute.
Conclusions
This study clearly shows that the bronchodilating effect as
reflected by the improvement in PEFR value at 15 minutes
was greater for NE–C900 as compared to Redimist.
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